Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752652 | 1.00 | PPM1D (0.32) | PPM1DPKMSMN1; SMN2 | |
| SCHEMBL21389421 | 0.84 | BRD4 (0.33) | PPM1D | |
| SCHEMBL28536009 | 0.84 | PLA2G7 (0.30) | — | |
| SCHEMBL21389115 | 0.84 | PLA2G7 (0.30) | — | |
| SCHEMBL28529851 | 0.84 | PLA2G7 (0.30) | — | |
| SCHEMBL28537661 | 0.84 | BRD4 (0.33) | PPM1D | |
| SCHEMBL26744875 | 0.84 | BRD4 (0.33) | PPM1D | |
| SCHEMBL9195877 | 0.82 | CHRM2 (0.31) | — | |
| SCHEMBL28532943 | 0.82 | APEX1 (0.35) | PPM1DSMN1; SMN2 | |
| SCHEMBL9195868 | 0.82 | CHRM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125386-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | PPM1D 138/4885PKM 2860/4885SMN1; SMN2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.